

RS 127445

Catalog No: tcsc0852



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

199864-86-3

Formula:

$C_{17}H_{17}ClFN_3$

Pathway:

Neuronal Signaling;GPCR/G Protein

Target:

5-HT Receptor;5-HT Receptor

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 31 mg/mL (97.55 mM)

Alternative Names:

MT 500

Observed Molecular Weight:

317.79


Product Description

RS 127445 is a novel high affinity, selective **5-HT_{2B}** receptor antagonist with **pK_i** of 9.5.

IC₅₀ & Target: pK_i: 5.5 (5-HT_{1A}), 2.7 (monoamine uptake), 1B/D), 3), 5), 6), 6.3 (5-HT_{2A}), 6.4 (5-HT_{2C}), 9.5 (5-HT_{2B})^[1]

In Vitro: RS-127445 is found to have nanomolar affinity for the 5-HT_{2B} receptor (pK_i=9.5±0.1) and 1,000 fold selectivity for this receptor as compared to numerous other receptor and ion channel binding sites. RS-127445 potently displaces [³H]-5-HT from human recombinant 5-HT_{2B} receptors expressed in CHO-K1 cells. The affinity (pK_i value) of RS-127445 for the 5-HT_{2B} receptor is 9.5±0.1 (n=9). RS-127445 is selective for the 5-HT_{2B} receptor, having approximately 1000 fold lower affinity for the human recombinant 5-HT_{2A}, 5-HT_{2C}, 5-HT₅, 5-HT₆ and 5-HT₇ receptors, a 5-HT_{1A} receptor in rat brain membranes, a 5-HT_{1B/D} receptor in bovine caudate, and a monoamine uptake site in rabbit platelets. RS-127445 potently blocks the 5-HT (10 nM) evoked increases in intracellular calcium concentrations in the HEK-293 cells expressing the 5-HT_{2B} receptor (pIC₅₀ of 10.4±0.1). In cells expressing human recombinant 5-HT_{2B} receptors, RS-127445 potently antagonizes 5-HT-evoked formation of inositol phosphates (pK_B=9.5±0.1) and 5-HT-evoked increases in intracellular calcium (pIC₁₀=10.4±0.1). RS-127445 also blocks 5-HT-evoked contraction of rat isolated stomach fundus (pA_{2B}=9.5±1.1) and (±)α-methyl-5-HT-mediated relaxation of the rat jugular vein (pA₂=9.9±0.3)^[1].

In Vivo: In rats, the fraction of RS-127445 that is bioavailable via the oral or intraperitoneal routes is 14 and 60% respectively. Intraperitoneal administration of RS-127445 (5 mg/kg) produced plasma concentrations predicted to fully saturate accessible 5-HT_{2B} receptors for at least 4 h. RS-127445 (5 mg/kg) is administered to rats by oral, intraperitoneal and intravenous routes. Peak plasma concentrations are rapidly achieved with the highest concentrations being found at the first time-point measured following intravenous and intraperitoneal administration (0.08 h) and by 0.25 h following dosing by the oral route of administration. RS-127445 is cleared from plasma with an estimated terminal elimination half-life of approximately 1.7 h. The bioavailability of RS-127445, when administered by the oral and intraperitoneal routes is approximately 14 and 62% of that obtained by intravenous administration. Approximately 60% of an intraperitoneal dose and 14% of the oral dose of RS-127445 (5 mg/kg) is bioavailable^[1]. RS-127445 (1-30 mg/kg), dose-dependently reduces faecal output, reaching significance at 10 and 30 mg/kg (n=6-11). In blood and brain, >98% of RS-127445 is protein-bound^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!